Overview

Gaucher Disease Treatment Market is poised to value over USD 2.4 billion during the forecast period 2022 to 2028.

Gaucher disease is an inherited, rare condition. The condition pertains to lipid metabolism. There is not enough of an enzyme called glucocerebrosidase if you have it. The result is that too much fatty substance builds up in the spleen, liver, lungs, bones, and even the brain. As a consequence, these organs are unable to function normally. 

After starting treatment with enzyme replacement therapy, miglustat (Zavesca), elglustat (Cerdelga), and osteoporosis drugs, many people suffering from Gaucher disease have seen improvements in their symptoms. The doctor might recommend a bone marrow transplant or splenectomy if your symptoms are too severe for less invasive treatments.

In recent years, the US Food and Drug Administration (FDA) has authorised a number of medications for illness treatment. Vpriv (velaglucerase alfa) was licenced by the FDA in 2010 as an enzyme replacement therapy (ERT) for type 1 Gaucher disease. Elelyso (taliglucerase alfa) and Cerdelga (eliglustat) were authorised by the FDA in 2012 and 2014, respectively, for type 1 Gaucher disease. These medications provide a choice of solutions based on individual needs, which is projected to drive market expansion.

The European Therapies Agency (EMA) and the US Food and Drug Administration (FDA) cooperated in July 2017 to encourage the adoption of novel techniques in the development of Gaucher disease medicines.

It is the most prevalent lysosomal storage disease, with a prevalence of 1 in every 50,000 live births. The perinatal fatal type of the illness is the most severe. Gaucher illness is thought to present itself most strongly in the Jewish community of Eastern and Central Europe, affecting 1 out of every 450 persons and 1 out of every 10 disease carriers within the descend. Increased medical progress in rare condition research and development is raising awareness and may eventually lead to a cure.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Gaucher Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Gaucher Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Gaucher Disease Treatment Market:
• Abbott
• Aptalis Pharma
• Genzyme Corporation
• GlaxoSmithKline (GSK)
• Pfizer Inc.
• Shire Human Genetic Therapies, Inc.
• Eli Lilly and Company
• Enobia Pharma Inc.
• Anthera Pharmaceuticals, Inc.
• BioMarin Pharmaceutical Inc.
• MedPro Rx
• Zymenex A/S
• Merck Serono
(Note: The list of the major players will be updated with the latest market scenario and trends)

Gaucher Disease Treatment Market Segmentation:
By Disease Type
• Type 1 (Neuropathic Forms)
• Type 2 (Perinatal Lethal Form)
• Type 3 (Slow-Neurologic Decay Form)

By Medication  
• Enzyme replacement therapy (ERT)
  o Imiglucerase (Cerezyme)
  o Velaglucerase alfa (VPRIV)
  o Taliglucerase alfa (Elelyso)
  o Others
• Substrate reduction therapy (SRT)
  o Glucosylceramide synthase inhibitors
       o Miglustat
       o Eliglustat
• Surgical
   o Bone marrow transplant
   o Spleen Removal

By End User
• Hospitals  
• Ambulatory Surgical Centers
• Clinical research institutes

By Region
• North America
• Europe
• Asia-Pacific
Latin America
• Middle East and Africa

Gaucher Disease Treatment Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Gaucher Disease Treatment Market By Disease Type, By Medication, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

$3450

Need Assistance

--------

UK : +44 141 628 9353
US : +1 347 709 4931

OR

Contact Sales

What you get


  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included


  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics